United States-based Bon Secours Mercy Health, a Catholic health care system, has collaborated with United States-based Lirio LLC, a behavioural engagement solution, it was reported yesterday.
The strategic partnership was announced at the 38th annual JP Morgan Healthcare Conference and was initiated by a direct investment from Bon Secours Mercy Health in Lirio's behaviour change AI platform. John Starcher, president and CEO of Bon Secours Mercy Health will join Lirio's board of directors.
Both firms will co-develop new behaviour change programs that influence health decision-making for those at risk for chronic diseases, such as diabetes and hypertension. These programs will gradually be marketed and sold to other health systems globally under commercial terms agreed to between both parties. Bon Secours Mercy Health will license and install present Lirio behaviour change programs, such as women's health programs and programs that encourage the use of digital engagement tools like patient portals.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults